New Developments in Lung Cancer Treatment. Lung cancer now accounts for 14% of all cancers but it is the most common cause of cancer death, In fact, more people die each year from lung cancer than from colon cancer, breast cancer, and prostate cancer combined. The 5-year survival rate of lung cancer is only 18% but the good news is that we have a lot of new medications that are giving patients with lung cancer longer and better lives. On our CME webcast, to discuss new treatments in lung cancer, are two of Ohio State’s experts in the management of lung cancer. Joining our moderator, Dr. Jim Allen, we have Dr. Greg Otterson who is a Professor of Internal Medicine from the Division of Medical Oncology and Dr. Erin Bertino, an Assistant Professor of Internal Medicine, also from the Division of Medical Oncology.
View a video introduction of this webcast
What you’ll learn in this webcast
As a result of this educational activity, webcast participants will be able to: GAIN an understanding of the importance of genomic testing in the initial workup of patients with lung cancer. EXPLAIN the evolving role of immune mediated therapy in lung cancer; RECOGNIZE the clinical benefit for patients receiving targeted therapies; and DESCRIBE the patient characteristics commonly associated with actionable mutations in lung cancer.
You’ll also learn about the following:
- The most fatal of all common cancers
- Evolving chemotherapy treatment of lung cancer
- Sub-classifying adenocarcinomas
- Squamous cell lung cancer treatment
- Large cell undifferentiated lung cancer
You can find this and many other MedNet21 programs on the OSU – CCME website.
Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at firstname.lastname@example.org.